Baillie Gifford Global Discovery B Acc
GlobalPricing frequency
Daily
Dealing cut off time
08:45
Type
OEIC
Yield
–
NAV
1,436.00p
Income frequency
Annually
Ongoing charge
0.78%
Latest actual NAV date
16-11-2026
ISIN
GB0006059330
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 31/10/2026 | % of assets |
|---|---|
| Oxford Nanopore Technologies PLC | 4.32 |
| Twist Bioscience Corp | 4.04 |
| Xometry Inc Ordinary Shares - Class A | 3.69 |
| Axon Enterprise Inc | 3.56 |
| Aspeed Technology Inc | 3.51 |
| Guardant Health Inc | 3.42 |
| Alnylam Pharmaceuticals Inc | 2.98 |
| Astera Labs Inc | 2.91 |
| Genmab AS | 2.82 |
| MercadoLibre Inc | 2.81 |
Investment objective
The Sub-fund aims to outperform (after deduction of costs) the S&P Global Small Cap Index, as stated in sterling, over rolling five-year periods. The Sub-fund will invest at least 90% in shares of companies. The Sub-fund will be actively managed and will invest in shares of companies in any country and in any sector which typically at the time of initial purchase have a market capitalisation which is smaller than or equal to the market capitalisation of the largest company in the S&P Global Small Cap Index (measured on the second business day of each calendar month) and that the Investment Adviser considers will offer excellent future growth prospects.